Alpha Cognition announces voluntary delisting from CSE by Investing.com

VANCOUVER, British Columbia & DALLAS–(BUSINESS WIRE)–Alpha Cognition Inc. (NASDAQ: ACOG) (Alpha Cognition, or the Company), announces that in connection with the listing of the Company on the Nasdaq Capital Market, the Company will voluntarily delist its common shares from the Canadian Stock Exchange.

The shares will be delisted from the Canadian Stock Exchange at the close of business on December 17, 2024. The Company’s common stock will continue to trade on the Nasdaq under the symbol ACOG.

About Alpha Cognition Inc.

Alpha Cognition Inc. is a commercial biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and cognitive impairment with mild traumatic brain injury (mTBI), for which there are currently no approved treatment options.

ZUNVEIL is a patented drug approved as a new generation acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEIL’s active metabolite differs from donepezil and rivastigmine in that it enhances the function of neuronal nicotinic receptors, particularly the alpha-7 subtype, which is known to have a positive effect on cognition. Benzgalantamine is also being developed in combination with memantine for the treatment of moderate to severe Alzheimer’s dementia and as an intranasal formulation for cognitive impairment with mTBI.

Forward-looking statements: This press release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this release may be forward-looking statements that reflect the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause actual results, levels activities, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although the Company believes it has a reasonable basis for any forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known to us and our expectations for the future, which we cannot be certain of. The Company cannot guarantee that actual results will be consistent with these forward-looking statements. These forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to revise or update any forward-looking statements for any reason, even if new information becomes available in the future.

See the original version on businesswire.com: https://www.businessvire.com/nevs/home/20241212186439/en/

For further information:
Michael McFadden, CEO
Phone: 1-858-344-4375
info@alphacognition.com

Source: Alpha Cognition Inc.